

ASX Announcement and Media Release

19 July 2004

SciGen Limited

SCI GEN'S INSULIN APPROVED FOR SALE IN INDIA

SciGen Limited ("SciGen") has received regulatory approval from the Drug Controller of India for commercial sale of its recombinant human insulin SciLin™.

SciGen managing director and chief executive officer, Mr Mark Compton said the approval was a key milestone for SciGen.

"The insulin market in India is very large with the incidence of diabetes in the country estimated at approximately 8 per cent and rising," Mr Compton said.

"In addition, medical treatment is becoming much more affordable in India as one consequence of India being one of the fastest growing economies in the Asia Pacific Region, if not the World," Mr Compton added.

SciGen's partners in India, Shreya Life Sciences and Ranbaxy Laboratories have indicated that each of their companies is ready to take SciGen's insulin to the Indian market soon after supply is received, which is expected in a few weeks.

SciGen has commercialisation agreements in place with Ranbaxy, India's largest pharmaceutical company and a global giant in generic drugs, and Shreya Life Sciences for marketing and sales of SciLin in India.

The combined sales force available to SciGen for insulin sales by virtue of these agreements, approximates 3,500 medical sales representatives, visiting about 2 million doctors in total.

In addition to this approval for insulin in India, SciGen has recently received approval for its human growth hormone, SciTropin™ in India and steps are being taken to launch the product within the next 90 days.

Working with SciGen's partner in China, the company has also recently submitted the registration dossier for human insulin. The agreement with SciGen's commercial partner in China comprehends minimum sales of US\$21M over three years following registration.

Mr Compton said the registration of human insulin in India represented a very significant success for SciGen's already-proven regulatory affairs team.

"The registration of biological pharmaceuticals in particular is a highly specialist area and SciGen's team has demonstrated again that the company has these skills and can use them to the benefit of SciGen's stakeholders," Mr Compton said.

Details on SciGen's other product registrations and sales can be found at the company's website.

The company's results for the 2004 financial year are expected to be announced on 27 August 2004.

About SciGen

SciGen Ltd is a biopharmaceutical company essentially involved in commercialising later stage research. It co-develops and markets genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which can allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices also in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland and the Netherlands.

=====ENDS=====

Media enquiries

Mark Compton
Managing Director & CEO
Telephone: +61 2 9234 1700

Web: www.scigen.com.au